12.46CHF-4.59%Mkt Cap: —P/E: —1d ago
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago …
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value295.67M $
Revenue (TTM)21.83M $
Gross Profit21.83M $
Net Income (TTM)-15.11M $
Revenue/Share1.093 USD
Last Price12.46 CHF
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees27
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-55.40
EV/Revenue13.55
P/S—
P/B-24.10
EPS (TTM)-0.85
EPS (Forward)—
52W Range
12.460% of range13.20
52W High13.20 CHF
52W Low12.46 CHF
Profitability
Gross Margin100.00%
Oper. Margin-83.59%
EBITDA Margin-24.45%
Profit Margin-69.22%
ROE—
ROA-5.65%
Growth
Revenue Growth-84.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF36.92M $
CapEx (TTM)—
FCF Margin205.61%
FCF Yield—
Net Debt10.60M $
Net Debt/EBITDA-1.99
Balance Sheet
Debt/Equity—
Current Ratio0.76
Quick Ratio0.70
Book Value/Sh-0.5179 CHF
Cash/Share1.443 CHF
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CHF
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.17.84M
Float17.99M
Insiders13.11%
Institutions10.68%
Technical
SMA 507.529 (+65.5%)
SMA 2005.823 (+114.0%)
Beta0.73
S&P 52W Chg18.16%
Avg Vol (30d)1.46K
Avg Vol (10d)2.29K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—